The KidCOVE study:
Enrollment open for young children in Moderna vaccine study
DETROIT, May 27, 2021 (AP): A Detroit-based health system is
enrolling children ages 6 months to 11 years old for
Moderna's COVID-19 vaccine study.
The KidCOVE study
will evaluate the safety and effectiveness of the pharma
company's mRNA-1273 vaccine for that age group, Henry Ford
Health System said Thursday.
The mRNA-1273 is the same vaccine given emergency use
authorization by the FDA for people 18 and older.
While children are far less likely than adults to get seriously
ill from COVID-19, they represent about 14% of the nation's
coronavirus cases. At least 316 have died in the U.S. alone,
according to a tally by the American Academy of Pediatrics.
Moderna said Tuesday that its vaccine strongly protects kids as
young as 12. Moderna said it will submit its teen data to the
U.S. Food and Drug Administration and other global regulators
early next month.
Earlier this month, the U.S. and Canada authorized another
vaccine—the shot made by Pfizer and BioNTech—to be
used starting at age 12. Pfizer also has started testing in
children 6 months to 11 years old. Experts hope to see some
results in the fall.
``The more vaccine candidates we have for our young people, the
better,'' said Dr. Adnan Munkarah, Henry Ford's executive
vice president and chief clinical officer.
Participation in the KidCOVE study will last about 14
months and require both in-person clinic visits and virtual
visits. Participants will receive one injection about 28 days
apart. Neither the participants or their parents will know
whether they received the study vaccine or a placebo injection,
according to Henry Ford.
All participants will be closely monitored by the study team.
Parents may sign up their children for KidCOVE at
the Henry Ford website.
Michigan has recorded 886,660 virus cases and 19,090 deaths
since the start of the pandemic more than a year ago, state
health officials reported Thursday.